NCT03375619

Long-term Follow-up Study of Patients Receiving CAR-T Cells

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Medical College of Wisconsin · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)

Detailed description

The objective is to follow participants receiving CAR-T cells from years 2 to 15 post-treatment for persistence of CAR-T cells, development of secondary malignancies, or other medical complications.

Conditions

• Chronic Lymphocytic Leukemia
• Lymphomas Non-Hodgkin's B-Cell
• Lymphoma, Small Lymphocytic
• Mantle Cell Lymphoma
• Central Nervous System Lymphoma
• Diffuse Large B Cell Lymphoma
• Follicular Lymphoma
• Burkitt Lymphoma
• Multiple Myeloma

Interventions

Type	Name	Description
OTHER	Long-Term Follow-Up of Participants who Received CAR-T cells	No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.

Timeline

• Start date: 2017-12-01
• Primary completion: 2035-01-01
• Completion: 2035-01-01
• First posted: 2017-12-18
• Last updated: 2025-11-10

Locations

1 site across 1 country: United States